Hipokin (Tiapride Hydrochloride)

Hipokin is indicated for several central nervous system disorders where dopaminergic overactivity contributes to symptoms. It is used under medical supervision for the following conditions:

• Schizophrenia, particularly when positive symptoms predominate.
• Acute agitation associated with psychotic or neuropsychiatric disorders.
• Chorea and other hyperkinetic movements in Huntington's disease.
• Additional movement disorders such as tardive dyskinesia or dystonia.
• Behavioral disturbances in neurodegenerative diseases when other therapies are insufficient.

• Tiapride hydrochloride acts as a selective antagonist at dopamine D2 and D3 receptors, primarily in the basal ganglia and limbic system. By blocking these receptors, it reduces excessive dopaminergic neurotransmission, which helps to control psychotic symptoms and abnormal involuntary movements without markedly affecting other neurotransmitter systems.

Adverse reactions to Hipokin can vary in frequency and severity.

Common

• Nausea or gastrointestinal discomfort.
• Dizziness or light‑headedness.
• Headache.
• Fatigue or somnolence.
• Dry mouth.

Serious

• Extrapyramidal symptoms such as rigidity or tremor.
• Neuroleptic malignant syndrome, a life‑threatening reaction.
• Severe hypotension or cardiac arrhythmia.
• Marked depression or emergence of suicidal thoughts.
• Severe allergic reactions including rash or angioedema.

When prescribing Hipokin, clinicians should consider several safety factors. Patients should be evaluated for:

• Known hypersensitivity to tiapride or related benzamide compounds.
• Existing hepatic or renal impairment, which may require dose adjustment.
• Cardiovascular disease, especially conditions predisposing to hypotension.
• Pregnancy or breastfeeding status, as safety data are limited.
• History of extrapyramidal disorders or neuroleptic malignant syndrome.
• The need for gradual discontinuation to avoid withdrawal phenomena.

Hipokin may interact with other medicines, influencing its safety or effectiveness.

Avoid

• Concurrent use of monoamine oxidase inhibitors (MAOIs).
• Other potent dopamine antagonists or high‑dose antipsychotics.
• Medications known to prolong the QT interval.
• Strong CYP450 inhibitors if the metabolic pathway is identified.

Use with caution

• Central nervous system depressants, including alcohol and benzodiazepines.
• Anticholinergic agents that may mask extrapyramidal signs.
• Antihypertensive drugs, due to additive blood‑pressure lowering effects.
• Serotonergic agents, because of potential serotonin syndrome.
• Other antipsychotics when combination therapy is considered.